Head-to-head · WeighScore
YOURx Health vs Zealthy
The verdict
YOURx Health takes it — 69.8/100 to 46.7/100.
YOURx Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. YOURx Health (yourxhealth.com) is a compounded GLP-1 telehealth platform powered by the MD Integrations provider network.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | YOURx Health | Zealthy |
|---|---|---|
| WeighScore | 69.8/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #118 | #496 |
| Semaglutide | $179/mo (compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $199/mo (compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #118 · C
Strengths
- Lab monitoring included (per the home page) — most peer platforms gate labs as add-ons or skip them entirely
- Physician video consultation with 'board-certified provider' disclosed
- MD Integrations network is a recognized white-label clinical platform
- Transparent published pricing: semaglutide injection $179/mo, tirzepatide injection $199/mo, oral RDT tablets $159-$179/mo
Where it loses points
- Parent company / legal entity name NOT publicly disclosed — material YMYL transparency gap
- NO LegitScript / NABP / PCAB / BBB seal displayed — material trust-signal gap vs peer platforms
- Per-state availability shown as 'Coverage 0 States' (placeholder metric) — appears the home page is incomplete or the platform is pre-launch
- Pharmacy partners NOT publicly named
- Confidence LOW until the platform exposes more public information
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.